Unlearn AI is building a platform to accelerate drug development with computational clinical trials. The current clinical trial procedure is slow due to time delays and enrollment challenges. As an alternative, Unlearn AI has created TwinRCTs that generate reliable evidence in a fraction of the time. TwinRCTs incorporate prognostic information from Digital Twins into randomized controlled trials (RCTs) to enable smaller, more efficient trials. Digital Twins are simulated control outcomes generated by AI models trained on historical data. A Digital Twin is created for a patient after their first medical visit, so disease progression can be predicted instead of waiting months for the trials to complete. To build their data, Unlearn AI is partnering with pharmaceutical companies.